New CFO in Panion, Sofia Josephson

Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.

The new CFO for Panion from the 1.st of January 2018 is Sofia Josephson, who has cooperated with Anni for a smooth transition and take-over of the role. Sofia Josephson has experience in accounting and financial controlling. She currently also works as Controller for VA Automotive, which is a company listed on First North. She has previously worked as accountant at PWC. Sofia Josephson has a Bachelor of Science in Economics from Kristianstad University.

Sofia Josephson holds no shares in the Company. 

Panion establishes an advisory board

Panion's strategic plans for the epilepsy project includes the establishment of a new advisory board. We are proud to announce that the first member is Dr. Karen Munana, Professor in neurology at North Carolina State University, College of veterinary medicine. She is a Doctor of Veterinary Medicine and holds a diplomate degree from the American College of Veterinary Internal Medicine (Neurology). She leads the Companion Animal Epilepsy Research Laboratory at NCSU, which is dedicated to developing more effective treatments for seizures in companion animals and to learn more about the cause of epileptic seizures in dogs and cats.

Advisory board membership is a voluntary, independent, and non-remunerated position. 

DECEMBER 29 2017

For further information, please contact:

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 

Nerladdningsbara filer

Information avseende budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löpte ut den 20 juni (-19).


Påminnelse angående budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löper ut den 20 juni (-19).





2019 Q1 report, Period January-March for Panion Animal Health AB

Period January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 663 (-697).
  • Earnings per share: SEK -0,07 (-0,05).
  • Liquidity at the end of the period: kSEK 4 961 (2 708).

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande


Kommuniké från årsstämma i Panion Animal Health AB (publ)

Idag, den 23 april 2019, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.


CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").



Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär